Building on decades of leadership in Waldenström’s macroglobulinemia research, Dana Farber Cancer Institute investigators have designed and led two early phase, institute initiated clinical trials that aim to overcome treatment resistance and reduce the need for indefinite therapy. These studies, one testing a fixed duration, chemotherapy free oral regimen and the other evaluating a precision antibody-drug conjugate, are reporting strong responses.
Click the link below to read or download the article:
Dana-Farber Cancer Institute drives deep remissions in Waldenström’s with targeted, time limited therapies